News | January 09, 2026
Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The approval is supported by data from three pivotal clinical trials
Applications include detailed scientific rationale and supporting clinical evidence
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
Subscribe To Our Newsletter & Stay Updated
